TY - JOUR
T1 - Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the multimodal treatment study of children with ADHD (MTA)
T2 - Part I: Executive summary
AU - Swanson, James
AU - Arnold, L. Eugene
AU - Kraemer, Helena
AU - Hechtman, Lily
AU - Molin, Brooke
AU - Hinshaw, Stephen
AU - Vitiello, Benedetto
AU - Jensen, Peter
AU - Steinhoff, Ken
AU - Lerner, Marc
AU - Greenhill, Laurence
AU - Abikoff, Howard
AU - Wells, Karen
AU - Epstein, Jeffery
AU - Elliott, Glen
AU - Newcorn, Jeffrey
AU - Hoza, Betsy
AU - Wigal, Timothy
PY - 2008/7
Y1 - 2008/7
N2 - Objective: To review the primary and secondary findings from the Multimodal Treatment study of ADHD (MTA) published over the past decade as three sets of articles. Method: In a two-part article-Part I: Executive Summary (without distracting details) and Part II: Supporting Details (with additional background and detail required by the complexity of the MTA)-we address confusion and controversy about the findings. Results: We discuss the basic features of the gold standard used to produce scientific evidence, the randomized clinical trial, for which was used to contrast four treatment conditions: medication management alone (MedMgt), behavior therapy alone (Beh), the combination of these two (Comb), and a community comparison of treatment "as usual" (CC). For each of the three assessment points we review three areas that we believe are important for appreciation of the findings: definition of evidence from the MTA, interpretation of the serial presentations of findings at each assessment point with a different definition of long-term, and qualification of the interim conclusions about long-term effects of treatments for ADHD. Conclusion: We discuss the possible clinical relevance of the MTA and present some practical suggestions based on current knowledge and uncertainties facing families, clinicians, and investigators regarding the long-term use of stimulant medication and behavioral therapy in the treatment of children with ADHD.
AB - Objective: To review the primary and secondary findings from the Multimodal Treatment study of ADHD (MTA) published over the past decade as three sets of articles. Method: In a two-part article-Part I: Executive Summary (without distracting details) and Part II: Supporting Details (with additional background and detail required by the complexity of the MTA)-we address confusion and controversy about the findings. Results: We discuss the basic features of the gold standard used to produce scientific evidence, the randomized clinical trial, for which was used to contrast four treatment conditions: medication management alone (MedMgt), behavior therapy alone (Beh), the combination of these two (Comb), and a community comparison of treatment "as usual" (CC). For each of the three assessment points we review three areas that we believe are important for appreciation of the findings: definition of evidence from the MTA, interpretation of the serial presentations of findings at each assessment point with a different definition of long-term, and qualification of the interim conclusions about long-term effects of treatments for ADHD. Conclusion: We discuss the possible clinical relevance of the MTA and present some practical suggestions based on current knowledge and uncertainties facing families, clinicians, and investigators regarding the long-term use of stimulant medication and behavioral therapy in the treatment of children with ADHD.
KW - Attention deficit/hyperactivity disorder
KW - Behavior modification
KW - Multimodal treatment
KW - Randomized clinical trial
KW - Stimulant medication
UR - http://www.scopus.com/inward/record.url?scp=45549085285&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=45549085285&partnerID=8YFLogxK
U2 - 10.1177/1087054708319345
DO - 10.1177/1087054708319345
M3 - Review article
C2 - 18573923
AN - SCOPUS:45549085285
SN - 1087-0547
VL - 12
SP - 4
EP - 14
JO - Journal of Attention Disorders
JF - Journal of Attention Disorders
IS - 1
ER -